Dren Bio is a biotechnology company developing powerful protein engineering technologies to deplete cells, protein aggregates and other disease-causing agents. Dren's lead programs are initially focused on hematologic neoplasms and solid cancers. Dren is actively working in other areas including auto-immune disorders and diseases of protein aggregation. Dren's team includes accomplished research and development personnel with strong collective industry experience.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/16/20 | $60,000,000 | Series A |
Alexandria Venture Investments BVF Partners HBM Healthcare Investments Mission BioCapital SR One  Taiho Ventures | undisclosed |
| 06/14/22 | $65,000,000 | Series B |
8VC Aisling Capital Alexandria Venture Investments ArrowMark Partners BVF Partners HBM Healthcare Investments Mission BioCapital Pfizer Strategic Investments Group Revelation Partners SR One Taiho Ventures | undisclosed |
